A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation

Computer Methods and Programs in Biomedicine

Volumn 110, Issue 2, 2013, Pages 203-214

  Germani, Massimiliano ^a   Del Bene, Francesca ^a   Rocchetti, Maurizio ^a   Van Der Graaf, Piet H ^b  

^a Accelera   (Italy)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Compartmental analysis; Matlab; Model based drug development; NONMEM; Pharmacokinetic and pharmacodynamic; Tumor Growth Inhibition model

Indexed keywords

COMPARTMENTAL ANALYSIS; DRUG DEVELOPMENT; EFFECTIVE COMMUNICATION; LARGE-SCALE DISTRIBUTION; MATHEMATICAL PRINCIPLE; MODELING AND SIMULATION; NONMEM; TUMOR GROWTH INHIBITION MODELS;

COMPUTER SIMULATION; COMPUTER SOFTWARE; PHARMACOKINETICS; RESEARCH;

MATLAB;

ACCELERA FOR SANDWICH; ARTICLE; CANCER INHIBITION; COMPUTER INTERFACE; COMPUTER LANGUAGE; COMPUTER PROGRAM; COMPUTER SIMULATION; MATHEMATICAL MODEL; MEDICAL RESEARCH; MONTE CARLO METHOD; PHARMACODYNAMICS; PHARMACOKINETICS; SKILL;

ABSORPTION; ALGORITHMS; COMPUTER GRAPHICS; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LINEAR MODELS; NEOPLASMS; PHARMACOKINETICS; PROGRAMMING LANGUAGES; SOFTWARE; STOCHASTIC PROCESSES;

EID: 84875896804     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2012.10.006     Document Type: Article

References (36)

1. Aarons L., Karlsson M.O., Mentre F., Rombout F., Steimer J.L., van PeerF A., invited COST B15 Experts Role of modelling and simulation in Phase I drug development. European Journal of Pharmaceutical Sciences 2001, 13(2):115-122.
2. Balant L.P., Gex-Fabry M. Modelling during drug development. European Journal of Pharmaceutics and Biopharmaceutics 2000, 50:13-26.
3. Bhattaram V.A., Bonapace C., Chilukuri D.M., Duan J.Z., Garnett C., Gobburu J.V.S., Jang S.H., Kenna L., Lesko L.J., Madabushi R., Men Y., Powell J.R., Qiu W., Ramchandani R.P., Tornoe C.W., Wang Y., Zheng J.J. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clinical Pharmacology & Therapeutics 2007, 81(2):213-221.
4. Burman C.F., Hamrèn B., Olsson P. Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics 2005, 4:47-58.
5. Gobburu J.V.S., Marroum P.J. Utilization of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clinical Pharmacokinetics 2001, 40:883-892.
6. Gobburu J.V.S. Pharmacometrics 2020. The Journal of Clinical Pharmacology 2010, 50:151S-157S.
7. Holford N., Ma S.C., Ploeger B.A. Clinical trial simulation: a review. Clinical Pharmacology & Therapeutics 2010, 88:166-182.
8. Karlsson M.O., Anehall T., Friberg L.E., Henningsson A., Kloft C., Sandstrom M., Xie R. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic & Clinical Pharmacology & Toxicology 2005, 96:206-211.
9. Krause A., Gieschke R. Interactive visualization and communication for increased impact of pharmacometrics. The Journal of Clinical Pharmacology 2010, 50:140S-145S.
10. Lalonde R.L., Kowalski K.G., Hutmacher M.M., Ewy W., Nichols D.J., Milligan P.A., Corrigan B.W., Lockwood P.A., Marshall S.A., Benincosa L.J., Tensfeldt T.G., Parivar K., Amantea M., Glue P., Koide H., Miller R. Model-based drug development. Clinical Pharmacology & Therapeutics 2007, 82:21-32.
11. Miller R., Ewy W., Corrigan B.W., Ouellet D., Hermann D., Kowalski K.G., Lockwood P., Koup J.R., Donevan S., El-Kattan A., Li C.S.W., Werth J.L., Feltner D.E., Lalonde R.L. How modeling and simulation have enhanced decision making in new drug development. Journal of Pharmacokinetics and Pharmacodynamics 2005, 32(2):185-197.
12. Mould D.R., Upton R.N. Basic concepts in population modeling, simulation, and model-based drug development. Pharmacometrics & Systems Pharmacology 2012, 1:e6. 10.1038/psp.2012.4.
13. Orloff J., Douglas F., Pinheiro J., Levinson S., Branson M., Chaturvedi P., Ette E., Gallo P., Hirsch G., Mehta C., Patel N., Sabir S., Springs S., Stanski D., Evers M.R., Fleming E., Singh N., Tramontin T., Golub H. The future of drug development: advancing clinical trial design. Nature Reviews Drug Discovery 2009, 8:949-957.
14. Peck C.C., Barr W.H., Benet L.Z., Collins J., Desjardins R.E., Furst D.E., Harter J.G., Levy G., Ludden T., Rodman J.H. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. The Journal of Clinical Pharmacology 1994, 34:111-119.
15. Van Der Graaf P.H., Gabrielsson J. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Medicinal Chemistry 2009, 1(8):1371-1374.
16. Beliveau M., Krishnan K. A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans. SAR and QSAR in Environmental Research 2005, 16:63-77.
17. Dansirikul A., Choi M., Duffull S.B. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel. Computers in Biology and Medicine 2005, 35:389-403.
18. Delboy H. A non-linear fitting program in pharmacokinetics with Microsoft Excel spreadsheet. International Journal of Bio-Medical Computing 1994, 37:1-14.
19. Meineke J., Brockmoller Simulation of complex pharmacokinetic models in Microsoft Excel. Computer Methods and Programs in Biomedicine 2007, 88:239-245.
20. Zhang Y., Huo M., Zhou J., Xie S., Solver P.K. An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in Biomedicine 2010, 99:306-314.
21. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2001, Swedish Pharmaceutical Press, Stockholm, Sweden. 3rd edition revised and expanded.
22. Beal S.L., Sheiner L.B. NONMEM Users Guide 1989, NONMEM Project Group, UCSF, San Francisco, CA.
23. Mager D.E., Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics 2001, 28:507-532.
24. Shampine L.F., Reichelt M.W. The MATLAB ODE Suite. SIAM Journal on Scientific Computing 1997, 18:1-22.
25. Shampine L.F., Reichelt M.W., Kierzenka J.A. Solving Index-1 DAEs in MATLAB and Simulink. SIAM Review 1999, 41:538-552.
26. Black J.W., Leff P. Operational models of pharmacological agonism. Proceedings of the Royal Society London B: Biological Sciences 1983, 220:141-162.
27. Ploeger B.A., van der Graaf P.H., Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD modeling). Drug Metabolism and Pharmacokinetics 2009, 24(1):3-15.
28. Ramsey S.J., Attkins N.J., Fish R., van der Graaf P.H. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. British Journal of Pharmacology 2011, 164(3):992-1007.
29. Magni P., Germani M., De Nicolao G., Bianchini G., Simeoni M., Poggesi I., Rocchetti M. A minimal model of tumor growth inhibition. IEEE Transactions on Biomedical Engineering 2008, 55(12):2683-2690.
30. Simeoni M., Magni P., Cammia C., De Nicolao G., Croci V., Pesenti E., Germani M., Poggesi I., Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Research 2004, 64:1094-1101.
31. Aston P.J., Derks G., Raji A., Agoram B.M., van der Graaf P.H. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. Journal of Theoretical Biology 2011, 281(1):113-121.
32. Christopoulos A., El-Fakahany E.E. Qualitative and quantitative assessment of relative agonist efficacy. Biochemical Pharmacology 1999, 58(5):735-748.
33. Gabrielsson J., Fjellström O., Ulander J., Rowley M., van der Graaf P.H. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Current Topics in Medicinal Chemistry 2011, 11:404-418.
34. Peletier L.A., Benson N., van der Graaf P.H. Impact of protein binding on receptor occupancy: a two-compartment model. Journal of Theoretical Biology 2010, 265:657-671.
35. Ross E.M., Kenakin T.P. Pharmacodynamics. Mechanisms of drug action and the relationship between drug concentration and effect. Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol. Tenth 2001, McGraw-Hill, New York. J.G. Hardman, L.E. Limbird (Eds.).
36. Terranova N., Magni P. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug. Computer Methods and Programs in Biomedicine 2012, 105:162-174.